AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Bioxytran, Inc.
Video analysis: BIXT
All videosNo video analysis for this stock yet. Request one from our team.
News: BIXT
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota's Department of Chemistry to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate research report by Globe Small Cap Research. The report Research Bioxytran as a multi-platform biotechnology story built around carbohydrate science, galectin antagonism, and oxygen-transport therapeutics, with active programs spanning antiviral therapy, stroke and hypoxia, and an emerging commercial bridge through the Company's A-SUQAR dietary supplement.
Similar companies
-
Glow Lifetech Corp.
GLWLF
·
Other OTC
Compare
-
Burzynski Research Institute, Inc.
BZYR
·
Other OTC
Compare
-
Theralink Technologies, Inc.
THER
·
Other OTC
Compare
-
Kane Biotech Inc.
KNBIF
·
Other OTC
Compare
-
BioVaxys Technology Corp.
BVAXF
·
Other OTC
Compare
-
Mosaic ImmunoEngineering Inc.
CPMV
·
Other OTC
Compare